Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of August 19, 2026, REPL trades at $14.92 with a market cap of $1.47B and a P/E ratio of -4.40. REPL moved -5.01% today. Year to date, REPL is +58.66%; over the trailing twelve months it is +180.22%. Its 52-week range spans $1.50 to $15.71. Analyst consensus is strong buy with an average price target of $18.00. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for REPL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $14.92 |
| Market Cap | $1.47B |
| P/E Ratio | -4.40 |
| EPS | $-3.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.71 |
| 52-Week Low | $1.50 |
| Volume | 3.11M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-313.94M |
| Gross Margin | 0.00% |
6 analysts cover REPL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.00.